These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17237372)

  • 1. Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer.
    Anderson MJ; Shafer-Weaver K; Greenberg NM; Hurwitz AA
    J Immunol; 2007 Feb; 178(3):1268-76. PubMed ID: 17237372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutting edge: delay and reversal of T cell tolerance by intratumoral injection of antigen-loaded dendritic cells in an autochthonous tumor model.
    Higham EM; Shen CH; Wittrup KD; Chen J
    J Immunol; 2010 Jun; 184(11):5954-8. PubMed ID: 20427765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity.
    Hermans IF; Ritchie DS; Yang J; Roberts JM; Ronchese F
    J Immunol; 2000 Mar; 164(6):3095-101. PubMed ID: 10706699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses.
    Nouri-Shirazi M; Banchereau J; Bell D; Burkeholder S; Kraus ET; Davoust J; Palucka KA
    J Immunol; 2000 Oct; 165(7):3797-803. PubMed ID: 11034385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.
    Redmond WL; Gough MJ; Charbonneau B; Ratliff TL; Weinberg AD
    J Immunol; 2007 Dec; 179(11):7244-53. PubMed ID: 18025166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
    Prins RM; Craft N; Bruhn KW; Khan-Farooqi H; Koya RC; Stripecke R; Miller JF; Liau LM
    J Immunol; 2006 Jan; 176(1):157-64. PubMed ID: 16365406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells.
    Shafer-Weaver KA; Watkins SK; Anderson MJ; Draper LJ; Malyguine A; Alvord WG; Greenberg NM; Hurwitz AA
    Cancer Res; 2009 Aug; 69(15):6256-64. PubMed ID: 19622771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of tumor-infiltrating CD8 T cells is tumor-dependent but antigen-independent.
    Olurinde MO; Shen CH; Drake A; Bai A; Chen J
    Cell Mol Immunol; 2011 Sep; 8(5):415-23. PubMed ID: 21666707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state.
    Grohmann U; Bianchi R; Ayroldi E; Belladonna ML; Surace D; Fioretti MC; Puccetti P
    J Immunol; 1997 Apr; 158(8):3593-602. PubMed ID: 9103420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD103- and CD103+ bronchial lymph node dendritic cells are specialized in presenting and cross-presenting innocuous antigen to CD4+ and CD8+ T cells.
    del Rio ML; Rodriguez-Barbosa JI; Kremmer E; Förster R
    J Immunol; 2007 Jun; 178(11):6861-6. PubMed ID: 17513734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic cells are required to initiate a Chlamydia trachomatis-specific CD8+ T cell response.
    Steele LN; Balsara ZR; Starnbach MN
    J Immunol; 2004 Nov; 173(10):6327-37. PubMed ID: 15528372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells.
    Grohmann U; Fallarino F; Silla S; Bianchi R; Belladonna ML; Vacca C; Micheletti A; Fioretti MC; Puccetti P
    J Immunol; 2001 Jan; 166(1):277-83. PubMed ID: 11123303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
    J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
    Kemp RA; Ronchese F
    J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
    Timmerman JM; Levy R
    J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective antigen cross-presentation by prostate cancer patients' dendritic cells: implications for prostate cancer immunotherapy.
    Orange DE; Jegathesan M; Blachère NE; Frank MO; Scher HI; Albert ML; Darnell RB
    Prostate Cancer Prostatic Dis; 2004; 7(1):63-72. PubMed ID: 14999241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
    Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
    J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
    Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
    J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.